Skip to main content

Repligen Corporation (RGEN)

Stock NASDAQ

$163.81

-6.48 (-3.81%)

Delayed quote.

Price history

Daily close
RGEN daily closing price, Nov 24, 2025 to Nov 20, 2026 Closed at $167.26 on Nov 24, 2025 and $163.81 on Nov 20, 2026, a change of -2.06%. Range $102.87 to $194.57.
Daily closes, Nov 24, 2025 to Nov 20, 2026 (250 trading days).
Start
$167.26
Latest close
$163.81
Period change
-2.06%
Period low
$102.87
Period high
$194.57

Key metrics

Market cap
$10.47B
Volume
697.7K
Average volume
1.20M
52-week range
$100.99 – $198.87
Beta
1.12
Last dividend
—
EPS (TTM)
-$0.21
P/E ratio
188.34
Revenue (TTM)
$805.61M
Net income (TTM)
-$11.80M
Total assets
$2.93B
Total debt
$692.24M
Cash and equivalents
$726.96M

Key financials (trailing twelve months).

Company profile

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

Sector
Healthcare
Industry
Medical - Instruments & Supplies
Exchange
NASDAQ
CEO
Olivier Loeillot
Employees
2,000
Headquarters
Waltham, MA, US
IPO date
1986-04-29

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Revenue$738.26M$634.44M$632.36M
Gross profit$347.62M$274.64M$278.44M
Operating income$59.58M-$35.11M$47.70M
EBITDA$182.51M$80.26M$145.32M
Net income$48.89M-$25.51M$35.60M
Diluted EPS$0.86-$0.46$0.63
Balance sheet
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Cash and equivalents$566.02M$757.36M$751.32M
Total assets$2.95B$2.83B$2.83B
Total liabilities$843.57M$856.95M$866.34M
Total debt$689.95M$686.25M$711.80M
Shareholders’ equity$2.11B$1.97B$1.96B
Cash flow statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Operating cash flow$117.42M$175.39M$113.92M
Capital expenditure-$23.52M-$32.91M-$38.99M
Free cash flow$93.90M$142.49M$74.93M

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Revenue$209.31M$204.13M$194.25M$197.91M$188.81M$182.37M
Gross profit$110.99M$108.36M$98.48M$93.44M$100.52M$91.14M
Operating income-$29.55M$11.93M$17.99M$18.56M$16.82M$13.90M
EBITDA-$1.97M$45.92M$32.31M$49.62M$46.94M$48.34M
Net income-$38.43M$5.01M$8.33M$13.29M$14.91M$14.87M
Diluted EPS-$0.68$0.09$0.15$0.23$0.26$0.26
Balance sheet
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Cash and equivalents$726.96M$606.78M$582.65M$566.02M$748.75M$708.86M
Total assets$2.93B$2.95B$2.93B$2.95B$2.92B$2.90B
Total liabilities$834.67M$838.15M$825.31M$843.57M$840.62M$839.89M
Total debt$692.24M$690.94M$687.62M$689.95M$688.87M$686.06M
Shareholders’ equity$2.09B$2.11B$2.11B$2.11B$2.08B$2.06B
Cash flow statement
MetricQ3 2026Sep 30, 2026Q2 2026Jun 30, 2026Q1 2026Mar 31, 2026Q4 2025Dec 31, 2025Q3 2025Sep 30, 2025Q2 2025Jun 30, 2025
Operating cash flow$43.10M$32.77M$28.30M$25.70M$48.10M$28.61M
Capital expenditure-$4.95M-$5.10M-$4.95M-$8.66M-$5.39M-$7.61M
Free cash flow$38.15M$27.67M$23.35M$17.05M$42.71M$21.00M